VR Logo

Unity Biotechnology Inc. (UBX) download report

Healthcare | Biotechnology & Pharma Research

Unity Biotechnology Inc. (UBX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

Please wait...

Please wait...

Please wait...

Please wait...

Please wait...

About The Company

Business: Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.

IPO Date: 03-May-2018

CEO & Director: Dr. Anirvan Ghosh Ph.D.

Co-Founder & Exec. Director: Dr. Nathaniel E. David A.B., Ph.D.

Listing: NASDAQ: UBX

Country: United States

Headquarters: South San Francisco, CA

Website: https://unitybiotechnology.com

Key Facts

Market cap: $41.43 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-63.88 Mln

Cash: $79.16 Mln

Total Debt: $48.71 Mln

Insider's Holding: 5.09%

Liquidity: Low

52 Week range: $0.57 - 4.97

Shares outstanding: 69,168,896

6 Years Aggregate:

  • CFO: $-307.19 Mln
  • EBITDA: $-304.29 Mln
  • Net Profit: $-327.54 Mln

Stock Performance

Time Period Unity Biotechnology (UBX) S&P BSE Sensex* S&P Small-Cap 600*
1 month-27.88-3.38-8.42
3 months-48.59-7.93-14.06
1 Year-86.260.55-17.64
3 Years-58.5310.416.75
5 Years--11.456.18
10 Years--12.0510.23
As on 28-Jun-2022 *As on 29-Jun-2022
Year Unity Biotechnology (UBX) S&P Small-Cap 600 S&P BSE Sensex